We have illustrated the potential of molecules 1a and 2a to inhibit NMD in a pathophysiological context by using lung cancer cells carrying a nonsense mutation in the tumor suppressor gene TP53 (Figure 5). This evidence concerns the gene TP53 and lung carcinoma.